Docoh
Loading...

LBPS 4d Pharma

Filed: 1 Apr 21, 7:15am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of April 2021

 

Commission File Number: 001-40106

 

4D pharma plc

(Translation of Registrant’s name into English)

 

5th Floor, 9 Bond Court

Leeds

LS1 2JZ

United Kingdom

Tel: +44 (0) 113 895 013

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 
 

 

Announcement of Final Results for Year Ended December 31, 2020

 

On April 1, 2021, 4D pharma plc (the “Company”) issued a press release to announce the final results for the Company for the year ended December 31, 2020.

 

A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 4D pharma plc
  
Date: April 1, 2021/s/ Duncan Peyton
 Duncan Peyton
 Chief Executive Officer

 

 
 

 

INDEX TO EXHIBITS

 

Exhibit  
Number Exhibit Title
     
99.1 Press Release, dated April 1, 2021.